ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
2,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2,3,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
3,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
4,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
4,2,Nervousness,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
4,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
4,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
5,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
5,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
6,1,Fixed eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
7,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
7,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
8,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
8,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
9,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
9,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
9,3,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
9,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
10,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
11,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
11,2,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
11,3,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
12,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
12,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
13,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
14,1,Coma,Coma states,Neurological disorders NEC,Nerv,N
14,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
14,3,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
14,4,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
15,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
15,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
16,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
16,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
17,1,Crohn's disease,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
17,2,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
17,3,Pharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
18,1,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
19,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
19,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
19,3,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
19,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
20,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
20,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
20,3,Impaired healing,Healing abnormal NEC,Tissue disorders NEC,Genrl,N
20,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
21,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
21,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
22,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
23,1,Ketonuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
24,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
24,2,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
24,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
25,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
25,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
26,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
27,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
28,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
29,1,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
30,1,Multiple injuries,Non-site specific injuries NEC,Injuries NEC,Inj&P,Y
30,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
31,1,Headache,Headaches NEC,Headaches,Nerv,N
31,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
32,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
32,2,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
32,3,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
32,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
33,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
34,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
35,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
35,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
35,3,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
35,4,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
36,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
37,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
38,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
38,2,Device failure,Device issues NEC,Device issues,Prod,N
39,1,Heart rate decreased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
39,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
39,3,Neck pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
40,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
40,2,Petechiae,Purpura and related conditions,Skin vascular abnormalities,Skin,N
40,3,Renal tubular necrosis,Renal vascular and ischaemic conditions,Renal disorders (excl nephropathies),Renal,N
40,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
41,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
42,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
42,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
42,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
42,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
42,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
42,6,Renal pain,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
43,1,Dermatitis acneiform,Acnes,Skin appendage conditions,Skin,N
44,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
45,1,Colon cancer metastatic,Colorectal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
45,2,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,N
45,3,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
46,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
47,1,Affect lability,Affect alterations NEC,Mood disorders and disturbances NEC,Psych,N
47,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
47,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
48,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
48,2,Status epilepticus,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
49,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
49,2,Skin depigmentation,Hypopigmentation disorders,Pigmentation disorders,Skin,N
49,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
50,1,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
51,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
51,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
51,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
52,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
52,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
53,1,Headache,Headaches NEC,Headaches,Nerv,N
53,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
54,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
55,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
55,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
55,3,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
56,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
57,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
57,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
58,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
59,1,Device failure,Device issues NEC,Device issues,Prod,N
59,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
59,3,Vein disorder,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
60,1,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
61,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
62,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
62,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
62,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
62,4,Headache,Headaches NEC,Headaches,Nerv,N
62,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
63,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
64,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
64,2,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
65,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
66,1,Congenital hand malformation,Musculoskeletal and connective tissue disorders of limbs congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
67,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
67,2,Headache,Headaches NEC,Headaches,Nerv,N
68,1,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
69,1,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
69,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
69,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
69,4,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
69,5,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
70,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
71,1,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
72,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
73,1,Multiple injuries,Non-site specific injuries NEC,Injuries NEC,Inj&P,Y
73,2,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
74,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
75,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
76,1,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
76,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
77,1,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
78,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
79,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
80,1,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
80,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
81,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
82,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
82,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
83,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
84,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
85,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
85,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
85,3,Panic attack,Panic attacks and disorders,Anxiety disorders and symptoms,Psych,N
86,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
86,2,Inflammation,Inflammations,General system disorders NEC,Genrl,N
86,3,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
86,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
86,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
86,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
87,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
87,2,Coma,Coma states,Neurological disorders NEC,Nerv,N
87,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
87,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
87,5,Therapeutic product effect increased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
88,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
88,2,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
89,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
89,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
89,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
89,4,Polydipsia,Fluid intake increased,Electrolyte and fluid balance conditions,Metab,N
89,5,Polyuria,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
89,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
90,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
90,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
91,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
91,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
92,1,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
92,2,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
93,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
93,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
94,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
95,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
96,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
97,1,Congenital oral malformation,Oral cavity disorders congenital NEC,Gastrointestinal tract disorders congenital,Cong,N
98,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
98,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
99,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
99,2,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
100,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
100,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
100,3,Ketosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
101,1,Diplopia,Visual disorders NEC,Vision disorders,Eye,N
101,2,Photophobia,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
101,3,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
102,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
103,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
104,1,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
104,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
105,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
106,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
107,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
108,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
109,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
109,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
109,3,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
109,4,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
110,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
110,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
111,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
112,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
112,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
113,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
114,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
114,2,Heart disease congenital,Cardiac disorders congenital NEC,Cardiac and vascular disorders congenital,Cong,N
115,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
115,2,Eye pruritus,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
115,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
115,4,Injection site infection,Infections NEC,Infections - pathogen unspecified,Infec,N
115,5,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
115,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
116,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
117,1,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
118,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
119,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
120,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
120,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
121,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
121,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
122,1,Ketonuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
122,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
123,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
123,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
124,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
125,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
125,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
126,1,Headache,Headaches NEC,Headaches,Nerv,N
126,2,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
127,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,Y
128,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
129,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
129,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
130,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
130,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
130,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
130,4,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
130,5,Thrombotic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
131,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
132,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
132,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
133,1,Pre-eclampsia,Hypertension associated disorders of pregnancy,Maternal complications of pregnancy,Preg,N
134,1,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
135,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
135,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
135,3,Depersonalisation/derealisation disorder,Dissociative states,Dissociative disorders,Psych,N
135,4,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
135,5,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
135,6,Head discomfort,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
136,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
136,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
137,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
137,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
137,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
137,4,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
137,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
137,6,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
137,7,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
138,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
139,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
140,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
140,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
141,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
141,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
142,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
142,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
143,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
143,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
143,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
144,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
144,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
144,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
144,4,Nervousness,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
145,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
146,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
147,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
148,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
149,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
149,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
149,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
149,4,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
149,5,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
150,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
150,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
150,3,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
150,4,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
151,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
151,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
151,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
152,1,Skin test positive,Immunology skin tests NEC,Immunology and allergy investigations,Inv,N
153,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
154,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
154,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
154,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
155,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
156,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
156,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
157,1,Pre-eclampsia,Hypertension associated disorders of pregnancy,Maternal complications of pregnancy,Preg,N
158,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
158,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
158,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
158,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
158,5,Hyperventilation,Breathing abnormalities,Respiratory disorders NEC,Resp,N
158,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
159,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
159,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
160,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
160,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
160,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
161,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
162,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
163,1,Retinal haemorrhage,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
164,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
165,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
166,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
167,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
167,2,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
168,1,Device failure,Device issues NEC,Device issues,Prod,N
168,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
168,3,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
169,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
170,1,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
170,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
170,3,Dysstasia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
170,4,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
170,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
171,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
172,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
172,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
173,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
174,1,Inflammation,Inflammations,General system disorders NEC,Genrl,N
175,1,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
175,2,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
176,1,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
176,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
176,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
177,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
177,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
178,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
179,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
179,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
179,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
179,4,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
179,5,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
180,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
180,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
181,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
181,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
181,3,Restlessness,Increased physical activity levels,Changes in physical activity,Psych,N
181,4,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
181,5,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
182,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
182,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
183,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
183,2,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
183,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
183,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
183,5,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
183,6,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
183,7,Ear disorder,Ear disorders NEC,Aural disorders NEC,Ear,N
183,8,Haemorrhoids,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
183,9,Headache,Headaches NEC,Headaches,Nerv,N
183,10,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
183,11,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
183,12,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
183,13,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
183,14,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
183,15,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
184,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
184,2,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
184,3,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
184,4,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
184,5,Coordination abnormal,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
184,6,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
184,7,Derealisation,Perception disturbances NEC,Disturbances in thinking and perception,Psych,N
184,8,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
184,9,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
184,10,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
184,11,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
184,12,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
184,13,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
184,14,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
184,15,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
184,16,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
184,17,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
184,18,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
184,19,Social avoidant behaviour,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
184,20,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
185,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
185,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
185,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
185,4,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
186,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
186,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
187,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
188,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
189,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
189,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
189,3,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
190,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
190,2,Coronary artery surgery,Arterial therapeutic procedures (excl aortic),Vascular therapeutic procedures,Surg,N
190,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
191,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
192,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
192,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
192,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
193,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
193,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
194,1,Nightmare,Parasomnias,Sleep disorders and disturbances,Psych,N
194,2,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
194,3,Therapeutic response delayed,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
195,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
196,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
196,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
196,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
196,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
197,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
197,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
198,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
199,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
199,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
199,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
200,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
201,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
201,2,Pancreatic neoplasm,Gastrointestinal neoplasms malignancy unspecified NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
202,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
203,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
203,2,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
203,3,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
203,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
204,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
204,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
204,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
204,4,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
205,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
205,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
206,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
206,2,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
206,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
206,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
206,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
207,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
207,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
207,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
207,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
208,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
208,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
209,1,Abdominal abscess,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
209,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
210,1,Breath odour,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
211,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
211,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
211,3,Laryngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
211,4,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
211,5,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
211,6,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
212,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
212,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
212,3,Headache,Headaches NEC,Headaches,Nerv,N
212,4,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
212,5,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
212,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
213,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
213,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
214,1,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,Y
214,2,Pulmonary malformation,Pulmonary and bronchial disorders congenital,Respiratory disorders congenital,Cong,N
214,3,Renal dysplasia,Renal disorders congenital,Renal and urinary tract disorders congenital,Cong,N
215,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
215,2,Eating disorder,Eating disorders NEC,Eating disorders and disturbances,Psych,N
215,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
215,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
215,5,Terminal state,General signs and symptoms NEC,General system disorders NEC,Genrl,N
216,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
217,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
217,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
218,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
218,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
218,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
218,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
219,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
219,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
220,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
221,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
221,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
222,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
222,2,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
222,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
223,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
223,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
224,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
225,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
226,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
226,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
226,3,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
227,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
228,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
228,2,Partial lipodystrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
228,3,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
229,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
229,2,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
230,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
230,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
231,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
232,1,Headache,Headaches NEC,Headaches,Nerv,N
233,1,Homicide,Criminal activity,Legal issues,SocCi,N
233,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,Y
234,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
234,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
234,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
235,1,Partial lipodystrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
235,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
236,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
236,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
236,3,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
236,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
237,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
238,1,Brain injury,Structural brain disorders NEC,Structural brain disorders,Nerv,N
238,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
238,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
238,4,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
239,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
239,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
239,3,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
240,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
241,1,Panophthalmitis,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
242,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
243,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
243,2,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
244,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
245,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
245,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
245,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
246,1,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
246,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
246,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
246,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
247,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
247,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
248,1,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
248,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
248,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
249,1,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
249,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
249,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
250,1,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
250,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
250,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
250,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
251,1,Cardiac death,Death and sudden death,Fatal outcomes,Genrl,Y
251,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
251,3,Generalised anxiety disorder,Anxiety disorders NEC,Anxiety disorders and symptoms,Psych,N
252,1,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
252,2,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
252,3,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
252,4,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
252,5,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
253,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
254,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
254,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
255,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
255,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
256,1,Apathy,Mood disorders NEC,Mood disorders and disturbances NEC,Psych,N
256,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
256,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
256,4,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
256,5,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
256,6,Eye irritation,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
256,7,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
256,8,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
256,9,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
256,10,Renal pain,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
256,11,Sluggishness,Asthenic conditions,General system disorders NEC,Genrl,N
256,12,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
256,13,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
257,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
257,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
257,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
257,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
257,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
257,6,Immobile,Disability issues,Lifestyle issues,SocCi,N
258,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
258,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
258,3,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
258,4,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
258,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
258,6,Foot fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
258,7,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
258,8,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
258,9,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
258,10,Muscle fatigue,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
258,11,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
258,12,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
259,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
259,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
259,3,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
259,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
259,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
259,6,Sneezing,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
259,7,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
259,8,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
260,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
261,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
262,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
262,2,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
263,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
263,2,Inflammation,Inflammations,General system disorders NEC,Genrl,N
263,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
264,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
264,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
264,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
264,4,Erythema nodosum,Panniculitides,Skin and subcutaneous tissue disorders NEC,Skin,N
264,5,Jaundice cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
264,6,Lipids increased,Lipoprotein and lipid tests NEC,Lipid analyses,Inv,N
264,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
264,8,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
264,9,Pancreatic carcinoma,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
264,10,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
264,11,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
264,12,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
265,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
265,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
265,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
265,4,Gastroenteritis viral,Viral infections NEC,Viral infectious disorders,Infec,N
265,5,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
265,6,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
265,7,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
266,1,Bacterial sepsis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
266,2,Cardiac death,Death and sudden death,Fatal outcomes,Genrl,Y
266,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
266,4,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
266,5,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
266,6,Retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
267,1,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
268,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
268,2,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
269,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
270,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
270,2,Cardiac failure chronic,Heart failures NEC,Heart failures,Card,N
270,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
271,1,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
271,2,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
272,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
273,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
273,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
274,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
274,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
274,3,Generalised oedema,Oedema NEC,General system disorders NEC,Genrl,N
274,4,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
274,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
274,6,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
275,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
275,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
275,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
276,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
276,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
277,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
277,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
277,3,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
277,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
278,1,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
278,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
278,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
278,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
279,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
280,1,Anti-insulin antibody positive,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
280,2,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
281,1,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
281,2,Urine flow decreased,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
282,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
282,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
282,3,Type I hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
283,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
283,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
283,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
284,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
284,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
285,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
285,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
285,3,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
286,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
286,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
287,1,Erythema multiforme,Bullous conditions,Epidermal and dermal conditions,Skin,N
287,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
287,3,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
287,4,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
287,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
288,1,Body height increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
288,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
288,3,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
288,4,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
288,5,Underweight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
289,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
289,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
289,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
289,4,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
290,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
290,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
290,3,Placental disorder,Placental abnormalities (excl neoplasms),"Placental, amniotic and cavity disorders (excl haemorrhages)",Preg,N
291,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
291,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
291,3,Prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
292,1,Congenital anomaly,Congenital disorders NEC,Congenital and hereditary disorders NEC,Cong,N
292,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
293,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
294,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
294,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
295,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
296,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
296,2,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
296,3,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
296,4,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
296,5,Breath odour,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
296,6,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
296,7,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
296,8,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
296,9,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
296,10,Personality change,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
296,11,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
296,12,Tension,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
297,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
298,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
299,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
300,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
300,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
301,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
302,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
302,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
303,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
303,2,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
304,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
304,2,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
305,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
305,2,Product name confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
305,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
306,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
307,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
308,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
308,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
308,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
308,4,Product selection error,Product selection errors and issues,Medication errors and other product use errors and issues,Inj&P,N
309,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
309,2,Product selection error,Product selection errors and issues,Medication errors and other product use errors and issues,Inj&P,N
310,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
310,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
311,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
311,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
311,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
311,4,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
312,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
313,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
313,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
313,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
314,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
314,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
314,3,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
315,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
315,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
315,3,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
316,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
316,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
317,1,Skin tightness,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
317,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
318,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
318,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
319,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
319,2,Pituitary-dependent Cushing's syndrome,Anterior pituitary hyperfunction,Hypothalamus and pituitary gland disorders,Endo,N
319,3,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
320,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
320,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
321,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
321,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
322,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
322,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
322,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
322,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
322,5,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
322,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
323,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
323,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
323,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
323,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
323,5,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
323,6,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
323,7,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
324,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
324,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
324,3,Ketonuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
325,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
325,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
326,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
326,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
326,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
326,4,Ketonuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
327,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
327,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
327,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
328,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
328,2,Pharyngeal hypoaesthesia,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
329,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
329,2,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
329,3,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
330,1,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
330,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
330,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
331,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
331,2,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
331,3,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
332,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
333,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
333,2,Low birth weight baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
333,3,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
334,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
334,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
334,3,Pre-eclampsia,Hypertension associated disorders of pregnancy,Maternal complications of pregnancy,Preg,N
335,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
336,1,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
337,1,Amputation,Limb therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
337,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
337,3,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,N
338,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
338,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
339,1,Nightmare,Parasomnias,Sleep disorders and disturbances,Psych,N
340,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
340,2,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
340,3,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
340,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
340,5,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
340,6,Pancreas transplant,Pancreatic therapeutic procedures,Gastrointestinal therapeutic procedures,Surg,N
340,7,Pancreas transplant rejection,Transplant rejections,Immune disorders NEC,Immun,N
341,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
342,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
342,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
342,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
343,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
344,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
344,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
345,1,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
345,2,Headache,Headaches NEC,Headaches,Nerv,N
345,3,Major depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
345,4,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
345,5,Retinopathy haemorrhagic,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
345,6,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
346,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
347,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
347,2,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
347,3,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
347,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
347,5,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
347,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
348,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
348,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
349,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
349,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
349,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
349,4,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
350,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
351,1,Blood disorder,Haematological disorders,Haematological disorders NEC,Blood,N
351,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
351,3,Blood pressure measurement,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
351,4,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
352,1,Coma,Coma states,Neurological disorders NEC,Nerv,N
352,2,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
352,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
352,4,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
352,5,Pathological fracture,Fractures NEC,Fractures,Musc,N
352,6,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
353,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
353,2,Injection site nodule,Injection site reactions,Administration site reactions,Genrl,N
353,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
353,4,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
354,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
354,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
355,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
355,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
356,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
356,2,Lacunar infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
356,3,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
357,1,Hernia,Hernias NEC,General system disorders NEC,Genrl,N
357,2,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
358,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
358,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
359,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
359,2,Hand fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
359,3,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
359,4,Musculoskeletal disorder,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
360,1,Meningomyelocele,Central nervous system disorders congenital NEC,Neurological disorders congenital,Cong,N
361,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
362,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
362,2,Hepatomegaly,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
362,3,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
363,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
363,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
364,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
364,2,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
365,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
365,2,Diabetic neuropathy,Chronic polyneuropathies,Peripheral neuropathies,Nerv,N
365,3,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
366,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
367,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
368,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
369,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
369,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
370,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
371,1,Extrasystoles,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
371,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
372,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
372,2,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
372,3,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
372,4,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
373,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
373,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
374,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
374,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
374,3,Proteinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
374,4,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
374,5,Systemic lupus erythematosus,Lupus erythematosus (incl subtypes),Connective tissue disorders (excl congenital),Musc,N
375,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
376,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
376,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
376,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
376,4,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
377,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
377,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
377,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
378,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
379,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
379,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
379,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
379,4,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
379,5,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
380,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
380,2,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
380,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
381,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
381,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
381,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
382,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
382,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
383,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
383,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
384,1,Acne,Acnes,Skin appendage conditions,Skin,N
384,2,Alopecia,Alopecias,Skin appendage conditions,Skin,N
384,3,Candida infection,Candida infections,Fungal infectious disorders,Infec,N
384,4,Ear infection,Ear infections,Infections - pathogen unspecified,Infec,N
384,5,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
384,6,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
384,7,Irritable bowel syndrome,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
384,8,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
384,9,Musculoskeletal pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
384,10,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
384,11,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
384,12,Pharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
384,13,Raynaud's phenomenon,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
384,14,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
384,15,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
385,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
386,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
386,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
387,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
387,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
387,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
388,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
388,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
389,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
390,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
390,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
390,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
391,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
392,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
392,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
392,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
392,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
393,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
393,2,Injection site nodule,Injection site reactions,Administration site reactions,Genrl,N
393,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
394,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
394,2,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
394,3,Nerve compression,Mononeuropathies,Peripheral neuropathies,Nerv,N
394,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
394,5,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
394,6,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
394,7,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
395,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
395,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
395,3,Skin induration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
396,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
396,2,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
396,3,Injection site macule,Injection site reactions,Administration site reactions,Genrl,N
396,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
396,5,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
396,6,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
396,7,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
396,8,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
397,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
398,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
398,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
399,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
399,2,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
399,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
399,4,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
399,5,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
399,6,Kidney infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
399,7,Urine ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
400,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
400,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
400,3,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
400,4,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
400,5,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
401,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
402,1,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
403,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
404,1,Bladder cancer,Bladder neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
405,1,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
405,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
406,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
406,2,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
407,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
408,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
408,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
409,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
409,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
409,3,Product tampering,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
410,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
410,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
411,1,Anger,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
411,2,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
411,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
411,4,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
411,5,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
411,6,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
411,7,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
411,8,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
411,9,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
411,10,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
411,11,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
411,12,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
411,13,Thyroid disorder,Thyroid disorders NEC,Thyroid gland disorders,Endo,N
411,14,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
412,1,Dementia Alzheimer's type,Alzheimer's disease (incl subtypes),Mental impairment disorders,Nerv,N
413,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
413,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
413,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
414,1,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
415,1,Craniofacial fracture,"Skull fractures, facial bone fractures and dislocations",Bone and joint injuries,Inj&P,N
415,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
416,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
416,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
417,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
417,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
418,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
418,2,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
418,3,Pancreatic calcification,Pancreatic disorders NEC,Exocrine pancreas conditions,Gastr,N
418,4,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
419,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
419,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
420,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
421,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
421,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
421,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
421,4,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
421,5,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
421,6,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
422,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
422,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
422,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
423,1,Brain injury,Structural brain disorders NEC,Structural brain disorders,Nerv,N
423,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
424,1,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
424,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
425,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
426,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
426,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
427,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
427,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
428,1,Conjunctivitis,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
428,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
428,3,Diabetic hyperglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
428,4,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
428,5,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
428,6,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
428,7,Eye discharge,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
428,8,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
428,9,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
428,10,Haemorrhoids,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
428,11,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
428,12,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
428,13,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
428,14,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
428,15,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
428,16,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
429,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
429,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
430,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
430,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
430,3,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
431,1,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
431,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
431,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
431,4,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
432,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
433,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
433,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
434,1,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
434,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
435,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
435,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
436,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
436,2,Carotid artery dissection,Central nervous system aneurysms and dissections,Central nervous system vascular disorders,Nerv,N
436,3,Cerebral artery occlusion,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
436,4,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
436,5,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
436,6,Monoplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
436,7,Vertebrobasilar artery dissection,Central nervous system aneurysms and dissections,Central nervous system vascular disorders,Nerv,N
437,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
437,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
437,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
438,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
438,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
439,1,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
440,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
440,2,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
440,3,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
441,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
441,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
442,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
442,2,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
442,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
443,1,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
444,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
444,2,Fracture,Fractures and dislocations NEC,Bone and joint injuries,Inj&P,N
444,3,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
445,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
446,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
446,2,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
447,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
447,2,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
448,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
448,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
449,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
449,2,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
449,3,Multiple sclerosis,Multiple sclerosis acute and progressive,Demyelinating disorders,Nerv,N
449,4,Osteomyelitis,Bone and joint infections,Infections - pathogen unspecified,Infec,N
449,5,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
450,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
450,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
450,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
450,4,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
451,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
451,2,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
452,1,Dementia Alzheimer's type,Alzheimer's disease (incl subtypes),Mental impairment disorders,Nerv,N
452,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
453,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
453,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
454,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
454,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
454,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
454,4,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
454,5,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
454,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
455,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
456,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
457,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
458,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
458,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
458,3,Foot fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
458,4,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
458,5,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
458,6,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
459,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
459,2,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
460,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
460,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
461,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
461,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
461,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
461,4,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
461,5,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
462,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
462,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
463,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
463,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
463,3,Lower limb fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
463,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
464,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
464,2,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
464,3,Headache,Headaches NEC,Headaches,Nerv,N
464,4,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
465,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
466,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
466,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
466,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
467,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
467,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
468,1,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
468,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
469,1,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
469,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
470,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
470,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
470,3,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
471,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
471,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
471,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
471,4,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
471,5,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
471,6,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
471,7,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
471,8,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
471,9,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
471,10,End stage renal disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
471,11,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
471,12,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
471,13,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
471,14,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
471,15,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
471,16,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
471,17,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
471,18,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
472,1,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
473,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
473,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
474,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
474,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
475,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
475,2,Dementia Alzheimer's type,Alzheimer's disease (incl subtypes),Mental impairment disorders,Nerv,N
476,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
477,1,Papule,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
477,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
478,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
478,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
478,3,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
478,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
478,5,Neutrophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
478,6,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
478,7,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
478,8,Wrong patient received product,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
479,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
480,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
480,2,Brain cancer metastatic,Central nervous system neoplasms malignant NEC,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
480,3,Lung neoplasm malignant,Respiratory tract and pleural neoplasms malignant cell type unspecified NEC,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
481,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
481,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
481,3,Brain fog,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
481,4,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
481,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
481,6,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
481,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
481,8,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
481,9,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
481,10,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
481,11,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
481,12,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
481,13,Weight fluctuation,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
482,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
482,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
482,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
482,4,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
482,5,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
483,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
484,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
484,2,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
485,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
485,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
486,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
486,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
486,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
486,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
486,5,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
487,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
487,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
487,3,Steroid therapy,Hormonal therapeutic procedures NEC,Endocrine gland therapeutic procedures,Surg,N
488,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
489,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
489,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
490,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
490,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
490,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
490,4,Deafness,Hearing losses,Hearing disorders,Ear,N
491,1,Cardiac complication associated with device,Cardiac complications associated with device,Complications associated with device,Genrl,N
491,2,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
492,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
492,2,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
493,1,Obesity,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
494,1,Abdominal transposition,Gastrointestinal tract disorders congenital NEC,Gastrointestinal tract disorders congenital,Cong,N
494,2,Congenital cardiovascular anomaly,Cardiovascular disorders congenital NEC,Cardiac and vascular disorders congenital,Cong,N
495,1,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
495,2,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
495,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
495,4,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
495,5,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
495,6,Incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
495,7,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
495,8,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
495,9,Respiration abnormal,Breathing abnormalities,Respiratory disorders NEC,Resp,N
496,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
496,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
496,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
496,4,Malabsorption,Malabsorption syndromes,Malabsorption conditions,Gastr,N
497,1,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
497,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
498,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
498,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
498,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
499,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
499,2,Product name confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
499,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
500,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
500,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
501,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
501,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
502,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
502,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
503,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
504,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
504,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
504,3,Laboratory test abnormal,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
505,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
506,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
506,2,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
506,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
506,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
506,5,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
507,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
507,2,Bacterial sepsis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
507,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
507,4,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
507,5,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
507,6,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
507,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
508,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
508,2,Gallbladder disorder,Gallbladder disorders NEC,Gallbladder disorders,Hepat,N
508,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
509,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
510,1,Laryngeal cancer,Laryngeal neoplasms malignant,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
511,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
511,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
511,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
511,4,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
512,1,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
512,2,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
512,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
513,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
513,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
513,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
514,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
514,2,Hypoglycaemia neonatal,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
514,3,Neonatal respiratory distress syndrome,Neonatal hypoxic conditions,Neonatal respiratory disorders,Resp,N
514,4,Sepsis neonatal,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
515,1,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
516,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
516,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
517,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
518,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
519,1,Foetal hypokinesia,Foetal complications NEC,Foetal complications,Preg,N
519,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
519,3,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
519,4,Premature delivery,Labour onset and length abnormalities,Maternal complications of labour and delivery,Preg,N
520,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
520,2,Low birth weight baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
520,3,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
521,1,Cholestasis of pregnancy,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
521,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
521,3,Postprandial hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
522,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
522,2,Foetal growth restriction,Foetal growth complications,Foetal complications,Preg,N
522,3,Foetal hypokinesia,Foetal complications NEC,Foetal complications,Preg,N
522,4,Small for dates baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
523,1,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
524,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
524,2,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
525,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
525,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
525,3,Counterfeit product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
525,4,Counterfeit product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
525,5,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
526,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
526,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
526,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
526,4,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
527,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
527,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
528,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
528,2,Blood test abnormal,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
528,3,Feeding disorder,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
528,4,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
528,5,Hiatus hernia,Diaphragmatic hernias,Abdominal hernias and other abdominal wall conditions,Gastr,N
528,6,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
528,7,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
528,8,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
529,1,Accidental underdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
529,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
529,3,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
529,4,Suicidal behaviour,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
529,5,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
530,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
530,2,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
530,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
530,4,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
530,5,Feeding disorder,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
530,6,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
530,7,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
530,8,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
531,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
531,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
531,3,Postprandial hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
531,4,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
531,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
532,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
532,2,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
532,3,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
532,4,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
532,5,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
533,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
533,2,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
534,1,Accidental underdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
534,2,Deafness,Hearing losses,Hearing disorders,Ear,N
534,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
534,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
534,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
535,1,Formication,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
535,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
535,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
535,4,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
536,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
536,2,Eating disorder,Eating disorders NEC,Eating disorders and disturbances,Psych,N
536,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
536,4,Formication,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
536,5,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
536,6,Musculoskeletal chest pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
536,7,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
536,8,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
536,9,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
536,10,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
536,11,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
536,12,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
537,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
538,1,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
538,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
539,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
539,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
539,3,Steroid therapy,Hormonal therapeutic procedures NEC,Endocrine gland therapeutic procedures,Surg,N
540,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
540,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
540,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
540,4,Small cell lung cancer,Respiratory tract small cell carcinomas,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
541,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
541,2,Muscle strain,"Muscle, tendon and ligament injuries",Injuries NEC,Inj&P,N
542,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
543,1,Allergy to chemicals,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
543,2,Allergy to metals,Allergic conditions NEC,Allergic conditions,Immun,N
543,3,Allergy to plants,Allergic conditions NEC,Allergic conditions,Immun,N
543,4,Fibromyalgia,Muscle pains,Muscle disorders,Musc,N
543,5,Glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
543,6,Herpes virus infection,Herpes viral infections,Viral infectious disorders,Infec,N
543,7,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
543,8,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
543,9,Macular oedema,"Retinal, choroid and vitreous infections and inflammations","Ocular infections, irritations and inflammations",Eye,N
543,10,Ocular hypertension,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
543,11,Osteoporosis,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
543,12,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
543,13,Vitreous detachment,"Choroid and vitreous structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
544,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
544,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
544,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
545,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
545,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
546,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
546,2,Coronary artery disease,Coronary artery disorders NEC,Coronary artery disorders,Card,N
546,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
547,1,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
547,2,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
547,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
547,4,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
547,5,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
547,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
547,7,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
547,8,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
548,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
548,2,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
548,3,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
548,4,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
548,5,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
549,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
550,1,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
550,2,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
550,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
551,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
551,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
552,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
552,2,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
552,3,Joint injury,Bone and joint injuries NEC,Bone and joint injuries,Inj&P,N
552,4,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
552,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
552,6,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
553,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
554,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
554,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
554,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
555,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
555,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
555,3,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
555,4,Fluid intake reduced,Fluid intake decreased,Electrolyte and fluid balance conditions,Metab,N
555,5,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
555,6,Headache,Headaches NEC,Headaches,Nerv,N
555,7,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
555,8,Hyperphagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
555,9,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
555,10,Infrequent bowel movements,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
555,11,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
555,12,Myalgia,Muscle pains,Muscle disorders,Musc,N
555,13,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
555,14,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
555,15,Thinking abnormal,Thinking disturbances,Disturbances in thinking and perception,Psych,N
555,16,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
555,17,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
556,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
557,1,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
558,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
558,2,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
559,1,Diverticulitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
559,2,Gastrointestinal carcinoma,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
559,3,Overweight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
560,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
560,2,Osteoarthritis,Osteoarthropathies,Joint disorders,Musc,N
561,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
562,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
562,2,Near death experience,Perception disturbances NEC,Disturbances in thinking and perception,Psych,N
562,3,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
562,4,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
563,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
564,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
564,2,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
564,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
564,4,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
565,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
566,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
566,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
566,3,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
566,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
566,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
566,6,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
566,7,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
567,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
567,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
567,3,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
567,4,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
567,5,Retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
567,6,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
568,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
568,2,Diverticulitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
568,3,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
568,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
568,5,Uterine prolapse,Pelvic prolapse conditions,"Uterine, pelvic and broad ligament disorders",Repro,N
569,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
569,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
569,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
570,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
570,2,Diabetic neuropathy,Chronic polyneuropathies,Peripheral neuropathies,Nerv,N
570,3,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
570,4,Obesity,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
570,5,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
570,6,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
570,7,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
570,8,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
571,1,Abscess limb,Infections NEC,Infections - pathogen unspecified,Infec,N
571,2,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
571,3,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
571,4,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
571,5,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
571,6,Skin wound,Skin injuries NEC,Injuries NEC,Inj&P,N
572,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
572,2,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
573,1,Bell's palsy,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
573,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
573,3,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
574,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
574,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
575,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
575,2,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
576,1,Rectal cancer,Colorectal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
577,1,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
577,2,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
578,1,Abnormal weight gain,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
578,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
578,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
578,4,Increased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
578,5,Pollakiuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
578,6,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
578,7,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
578,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
579,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
579,2,Diabetic eye disease,Ocular disorders NEC,Eye disorders NEC,Eye,N
580,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
580,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
580,3,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
581,1,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
581,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
581,3,Nervousness,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
581,4,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
582,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
582,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
582,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
583,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
584,1,Localised infection,Infections NEC,Infections - pathogen unspecified,Infec,N
585,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
585,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
586,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
586,2,Counterfeit product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
586,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
586,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
586,5,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
587,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
587,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
587,3,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
588,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
588,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
589,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
589,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
589,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
590,1,Ichthyosis,Skin and subcutaneous tissue disorders congenital NEC,Skin and subcutaneous tissue disorders congenital,Cong,N
590,2,Injection site discolouration,Injection site reactions,Administration site reactions,Genrl,N
590,3,Lipodystrophy acquired,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
590,4,Skin hypertrophy,Skin hyperplasias and hypertrophies,Cornification and dystrophic skin disorders,Skin,N
590,5,Skin plaque,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
591,1,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
591,2,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
591,3,Glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
591,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
591,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
591,6,Neuropathic arthropathy,Osteoarthropathies,Joint disorders,Musc,N
591,7,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
591,8,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
592,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
592,2,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
593,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
593,2,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
594,1,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
594,2,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
595,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
596,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
596,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
596,3,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
597,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
597,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
597,3,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
598,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
598,2,Drug administered in wrong device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
598,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
599,1,Skin test positive,Immunology skin tests NEC,Immunology and allergy investigations,Inv,N
600,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
600,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
601,1,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
602,1,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
602,2,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
603,1,Oesophageal carcinoma,Oesophageal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
604,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
604,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
604,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
604,4,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
605,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
605,2,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
605,3,Diverticulitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
605,4,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
605,5,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
606,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
606,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
606,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
606,4,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
607,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
607,2,Corneal disorder,Corneal disorders NEC,Eye disorders NEC,Eye,N
607,3,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
608,1,Ketosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
609,1,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
610,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
610,2,Intercepted product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
611,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
611,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
612,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
613,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
613,2,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
613,3,Vitreous haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
614,1,Accidental underdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
614,2,Diabetic eye disease,Ocular disorders NEC,Eye disorders NEC,Eye,N
615,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
615,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
616,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
617,1,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
617,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
618,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
619,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
619,2,"Sleep disorder due to general medical condition, insomnia type",Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
619,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
620,1,Generalised oedema,Oedema NEC,General system disorders NEC,Genrl,N
621,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
621,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
622,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
623,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
624,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
625,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
626,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
626,2,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
626,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
627,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
627,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
627,3,Type 2 diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
628,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
628,2,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
629,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
630,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
630,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
631,1,Head discomfort,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
631,2,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
631,3,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
631,4,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
632,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
632,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
633,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
634,1,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
634,2,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
635,1,Infusion site irritation,Infusion site reactions,Administration site reactions,Genrl,N
635,2,Infusion site pain,Infusion site reactions,Administration site reactions,Genrl,N
635,3,Infusion site vesicles,Infusion site reactions,Administration site reactions,Genrl,N
636,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
636,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
637,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
637,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
637,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
638,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
639,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
639,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
640,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
640,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
640,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
641,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
642,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
642,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
642,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
643,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
644,1,Blood blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
644,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
644,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
644,4,Blood viscosity increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
644,5,Brain fog,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
644,6,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
644,7,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
644,8,Protein total increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
644,9,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
645,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
645,2,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
645,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
646,1,Infusion site haemorrhage,Infusion site reactions,Administration site reactions,Genrl,N
647,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
647,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
648,1,Device dislocation,Device issues NEC,Device issues,Prod,N
648,2,Diabetic neuropathy,Chronic polyneuropathies,Peripheral neuropathies,Nerv,N
648,3,Foot deformity,Extremity deformities,Musculoskeletal and connective tissue deformities (incl intervertebral disc disorders),Musc,N
648,4,Limb injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
648,5,Osteomyelitis,Bone and joint infections,Infections - pathogen unspecified,Infec,N
649,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
649,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
650,1,Arthropathy,Arthropathies NEC,Joint disorders,Musc,N
650,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
651,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
652,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
653,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
654,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
655,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
655,2,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
656,1,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
657,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
657,2,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
658,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
658,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
659,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
659,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
660,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
660,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
661,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
661,2,Fine motor skill dysfunction,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
662,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
663,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
663,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
664,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
664,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
665,1,Accidental underdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
665,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
666,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
667,1,Deformity,General signs and symptoms NEC,General system disorders NEC,Genrl,N
667,2,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
667,3,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
668,1,Abdominal abscess,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
668,2,Infusion site irritation,Infusion site reactions,Administration site reactions,Genrl,N
668,3,Infusion site pain,Infusion site reactions,Administration site reactions,Genrl,N
668,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
669,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
670,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
670,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
671,1,Aortic stenosis,Aortic necrosis and vascular insufficiency,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
671,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
671,3,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
671,4,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
671,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
671,6,Type 2 diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
672,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
673,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
673,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
673,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
674,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
674,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
675,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
675,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
676,1,Throat tightness,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
677,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
678,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
679,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
680,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
680,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
680,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
680,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
681,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
681,2,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
682,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
683,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
684,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
684,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
685,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
686,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
687,1,Infusion site reaction,Infusion site reactions,Administration site reactions,Genrl,N
688,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
688,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
689,1,Infusion site reaction,Infusion site reactions,Administration site reactions,Genrl,N
690,1,Infusion site reaction,Infusion site reactions,Administration site reactions,Genrl,N
691,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
691,2,Coma,Coma states,Neurological disorders NEC,Nerv,N
691,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
691,4,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
692,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
693,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
693,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
694,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
694,2,Infusion site erythema,Infusion site reactions,Administration site reactions,Genrl,N
694,3,Infusion site mass,Infusion site reactions,Administration site reactions,Genrl,N
694,4,Infusion site pain,Infusion site reactions,Administration site reactions,Genrl,N
694,5,Infusion site pruritus,Infusion site reactions,Administration site reactions,Genrl,N
695,1,Cutaneous amyloidosis,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
695,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
696,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
697,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
697,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
698,1,Infusion site pain,Infusion site reactions,Administration site reactions,Genrl,N
699,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
700,1,Accidental underdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
700,2,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
700,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
700,4,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
701,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
701,2,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
702,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
703,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
703,2,Infusion site erythema,Infusion site reactions,Administration site reactions,Genrl,N
704,1,Brain injury,Structural brain disorders NEC,Structural brain disorders,Nerv,N
704,2,Deafness,Hearing losses,Hearing disorders,Ear,N
705,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
706,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
707,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
707,2,Headache,Headaches NEC,Headaches,Nerv,N
707,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
708,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
708,2,Foreign body sensation in eyes,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
708,3,Genital infection male,Male reproductive tract infections,Infections - pathogen unspecified,Infec,N
708,4,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
708,5,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
708,6,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
709,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
709,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
709,3,Product name confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
709,4,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
710,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
710,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
711,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
711,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
712,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
713,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
713,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
714,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
715,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
715,2,Atrial flutter,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
715,3,Bowen's disease,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
715,4,Cardiac failure chronic,Heart failures NEC,Heart failures,Card,N
715,5,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
715,6,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
715,7,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
715,8,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
715,9,Diabetic neuropathy,Chronic polyneuropathies,Peripheral neuropathies,Nerv,N
715,10,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
715,11,Dyslipidaemia,Lipid metabolism and deposit disorders NEC,Lipid metabolism disorders,Metab,N
715,12,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
715,13,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
715,14,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
715,15,Injection site plaque,Injection site reactions,Administration site reactions,Genrl,N
715,16,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
715,17,Obesity,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
715,18,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
715,19,Upper respiratory tract infection,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
715,20,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
715,21,Vitamin D deficiency,Fat soluble vitamin deficiencies and disorders,Vitamin related disorders,Metab,N
716,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
717,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
717,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
717,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
717,4,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
718,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
718,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
719,1,Infusion site reaction,Infusion site reactions,Administration site reactions,Genrl,N
720,1,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
720,2,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
720,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
720,4,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
720,5,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
720,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
720,7,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
720,8,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
721,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
721,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
722,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
723,1,Infusion site hypersensitivity,Infusion site reactions,Administration site reactions,Genrl,N
723,2,Infusion site inflammation,Infusion site reactions,Administration site reactions,Genrl,N
723,3,Infusion site irritation,Infusion site reactions,Administration site reactions,Genrl,N
724,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
724,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
725,1,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
726,1,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
727,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
728,1,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
729,1,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
730,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
731,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
732,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
733,1,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
734,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
734,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
734,3,Migraine,Migraine headaches,Headaches,Nerv,N
734,4,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
735,1,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
735,2,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
735,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
735,4,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
736,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
737,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
737,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
737,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
738,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
738,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
739,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
740,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
740,2,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
740,3,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
740,4,Thyroid disorder,Thyroid disorders NEC,Thyroid gland disorders,Endo,N
741,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
741,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
742,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
742,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
743,1,Addison's disease,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
743,2,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
743,3,Autoimmune disorder,Autoimmune disorders NEC,Autoimmune disorders,Immun,N
743,4,Autonomic nervous system imbalance,Autonomic nervous system disorders,Neuromuscular disorders,Nerv,N
743,5,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
743,6,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
743,7,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
743,8,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
743,9,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
743,10,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
743,11,Mast cell activation syndrome,Haematological disorders,Haematological disorders NEC,Blood,N
743,12,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
743,13,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
743,14,Post-acute COVID-19 syndrome,Coronavirus infections,Viral infectious disorders,Infec,N
743,15,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
743,16,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
743,17,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
743,18,Wrong technique in device usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
744,1,Inflammation,Inflammations,General system disorders NEC,Genrl,N
745,1,Angiopathy,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
745,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
745,3,Dementia Alzheimer's type,Alzheimer's disease (incl subtypes),Mental impairment disorders,Nerv,N
745,4,Feeding disorder,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
745,5,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
746,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
747,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
748,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
748,2,Headache,Headaches NEC,Headaches,Nerv,N
748,3,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
748,4,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
748,5,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
749,1,Infusion site haemorrhage,Infusion site reactions,Administration site reactions,Genrl,N
750,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
751,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
751,2,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
751,3,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
751,4,Headache,Headaches NEC,Headaches,Nerv,N
751,5,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
751,6,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
751,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
751,8,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
751,9,Throat tightness,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
751,10,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
751,11,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
752,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
752,2,Headache,Headaches NEC,Headaches,Nerv,N
752,3,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
752,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
752,5,Oropharyngeal discomfort,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
752,6,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
752,7,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
753,1,Catheter site pain,Implant and catheter site reactions,Administration site reactions,Genrl,N
753,2,Catheter site related reaction,Implant and catheter site reactions,Administration site reactions,Genrl,N
753,3,Skin mass,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
754,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
755,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
755,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
756,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
756,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
757,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
758,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
758,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
759,1,Infusion site pain,Infusion site reactions,Administration site reactions,Genrl,N
760,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
760,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
761,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
761,2,Bronchiolitis,Viral infections NEC,Viral infectious disorders,Infec,N
761,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
761,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
762,1,Injection site nodule,Injection site reactions,Administration site reactions,Genrl,N
763,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
764,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
765,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
766,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
766,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
767,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
768,1,Parkinsonism,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
769,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
769,2,Product label counterfeit,"Counterfeit, falsified and substandard products","Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
770,1,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
771,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
771,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
771,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
772,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
772,2,Counterfeit product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
773,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
773,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
774,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
774,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
774,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
775,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
776,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
777,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
777,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
778,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
778,2,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
779,1,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
779,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
780,1,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
780,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
781,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
782,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
782,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
783,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
783,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
783,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
784,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
785,1,Infusion site pain,Infusion site reactions,Administration site reactions,Genrl,N
786,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
786,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
787,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
787,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
788,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
789,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
789,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
789,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
789,4,Limb discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
789,5,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
790,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
790,2,Feeling drunk,Feelings and sensations NEC,General system disorders NEC,Genrl,N
790,3,Headache,Headaches NEC,Headaches,Nerv,N
790,4,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
790,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
790,6,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
791,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
791,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
792,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
793,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
793,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
794,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
795,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
795,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
796,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
796,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
797,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
798,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
799,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
799,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
799,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
799,4,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
800,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
800,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
800,3,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
800,4,Limb discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
800,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
801,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
802,1,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
803,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
803,2,Conversion disorder,Somatic symptom disorders,Somatic symptom and related disorders,Psych,N
803,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
804,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
805,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
805,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
806,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
806,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
807,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
808,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
808,2,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
809,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
809,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
810,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
810,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
811,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
811,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
811,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
812,1,Circadian rhythm sleep disorder,Disturbances in sleep phase rhythm,Sleep disturbances (incl subtypes),Nerv,N
812,2,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
812,3,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
812,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
812,5,Oral herpes,Herpes viral infections,Viral infectious disorders,Infec,N
812,6,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
813,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
814,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
814,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
815,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
816,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
817,1,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
818,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
818,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
819,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
819,2,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
820,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
820,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
820,3,Glycosylated haemoglobin abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
820,4,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
820,5,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
821,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
821,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
822,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
822,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
823,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
824,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
825,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
825,2,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
826,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
827,1,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
828,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
828,2,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
829,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
830,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
831,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
832,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
833,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
834,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
834,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
835,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
835,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
836,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
836,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
837,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
838,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
839,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
840,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
841,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
842,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
842,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
842,3,Emotional disorder,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
843,1,Deafness,Hearing losses,Hearing disorders,Ear,N
844,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
845,1,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
845,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
845,3,Injury,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
846,1,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
846,2,Wrong patient received product,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
847,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
847,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
848,1,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
849,1,Infusion site pain,Infusion site reactions,Administration site reactions,Genrl,N
850,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
851,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
851,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
851,3,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
852,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
853,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
854,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
855,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
855,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
855,3,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
855,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
856,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
857,1,Bladder cancer,Bladder neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
857,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
857,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
857,4,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
858,1,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
859,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
859,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
860,1,Carpal tunnel syndrome,Mononeuropathies,Peripheral neuropathies,Nerv,N
861,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
861,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
861,3,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
861,4,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
861,5,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
861,6,Feeding disorder,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
861,7,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
861,8,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
861,9,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
861,10,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
861,11,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
861,12,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
861,13,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
862,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
862,2,Fungal skin infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
863,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
864,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
864,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
864,3,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
865,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
865,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
865,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
865,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
865,5,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
866,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
867,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
868,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
869,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
869,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
870,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
870,2,Gastroenteritis viral,Viral infections NEC,Viral infectious disorders,Infec,N
870,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
871,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
871,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
872,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
872,2,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
873,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
873,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
874,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
874,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
874,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
874,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
874,5,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
875,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
875,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
875,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
875,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
876,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
876,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
876,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
876,4,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
877,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
877,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
878,1,Hypermetropia,Refractive and accommodative disorders,Vision disorders,Eye,N
879,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
880,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
881,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
881,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
882,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
882,2,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
882,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
882,4,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
883,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
884,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
885,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
886,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
887,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
888,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
889,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
889,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
890,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
890,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
891,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
892,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
892,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
893,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
894,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
894,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
895,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
896,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
897,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
898,1,Blood insulin increased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
898,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
898,3,Insulin C-peptide decreased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
898,4,Insulinoma,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
898,5,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
899,1,Blood insulin increased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
899,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
899,3,Insulin C-peptide decreased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
899,4,Insulin autoimmune syndrome,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
899,5,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
900,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
901,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
901,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
901,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
902,1,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
903,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
903,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
904,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
905,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
905,2,Glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
905,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
906,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
906,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
907,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
908,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
909,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
909,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
910,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
911,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
911,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
912,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
913,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
913,2,Incorrect dose administered by product,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
914,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
914,2,Incorrect dose administered by product,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
915,1,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
915,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
916,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
917,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
917,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
918,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
919,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
919,2,Incorrect dose administered by product,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
920,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
921,1,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
922,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
923,1,Gastrointestinal carcinoma,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
923,2,Limb discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
923,3,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
924,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
924,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
924,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
924,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
924,5,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
925,1,Abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
925,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
925,3,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
925,4,Device use error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
925,5,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
925,6,Oxygen saturation decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
925,7,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
926,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
926,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
926,3,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
926,4,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
926,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
926,6,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
926,7,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
927,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
927,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
928,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
928,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
928,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
929,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
930,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
930,2,Panic reaction,Panic attacks and disorders,Anxiety disorders and symptoms,Psych,N
931,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
932,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
932,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
932,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
933,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
933,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
933,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
933,4,Intentional device use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
934,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
934,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
935,1,Infusion site pain,Infusion site reactions,Administration site reactions,Genrl,N
936,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
936,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
937,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
937,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
937,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
937,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
938,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
938,2,Carbon dioxide decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
938,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
938,4,Oxygen saturation decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
938,5,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
939,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
939,2,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
939,3,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
940,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
941,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
941,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
942,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
943,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
943,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
944,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
944,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
945,1,Infusion site pain,Infusion site reactions,Administration site reactions,Genrl,N
946,1,Hand fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
946,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
947,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
947,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
948,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
948,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
948,3,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
948,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
949,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
950,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
950,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
